Israeli medical marijuana firm Cannabotech is exploring how different combinations of cannabinoids, herbs, and mushrooms could treat a variety of illnesses.
Israeli medical marijuana firm Cannabotech is currently researchinghow specific blends of cannabinoids, medicinal herbs, and mushrooms could effectively treat a variety of medical conditions. So far, the company has developed five specific blends intended to treat colon cancer, infertility, fatty liver, inflammation, and heart or vascular disease. These products are all currently awaiting clinical trials.
“Every cannabis plant has 30-40 cannabinoids that are active in the body and a total of several hundred cannabinoids,” said Cannabotech cofounder and CEO Elchanan Shaked to Globes. “We believe that the secret to the plant’s activity lies in cannabinoids that appear in small quantities in the plant. If you change the ratios between them and increase their concentration in the final product, very high medical effectiveness and unique compounds for treatment of various diseases can be attained.”
Shaked told Globes that his company will “use science” to prove that his company’s unique ratios of cannabinoids will prove more effective than ratios found in naturally-grown plants. Other researchers are also currently working to create their own specific blends of cannabinoids to target specific illnesses, but Cannabotech is taking the idea one step further by including mushrooms in the mix.
“Penicillin originates in mushrooms, as does chemotherapy,” Shaked explained. “The benefits of mushrooms have been the subject of research for thousands of years. Prof. Solomon Wasser has been researching mushrooms at the University of Haifa for decades. He has huge libraries containing ingredients from mushrooms and the information that he has gathered over the years about treatment using them and their interactions with other ingredients.”
Another feature that sets Cannabotech apart from other medical marijuana research companies is the fact that it intends to crowdsource its funding, rather than relying on private investment. “We believe in building the company from below, without direction from capital market people,” Shaked said. “I believe in raising capital from the public, but without receipts.”
So far, it seems like Cannabotech is looking to stick to non-psychedelic mushrooms for its cannabis blends, but a growing body of research is proving that psilocybin can be as effective a medicine as medical marijuana.
Recent studies have found that psilocybin can help patients overcome treatment-resistant depression, alcoholism, or anxiety, and current trials are exploring how this psychedelic fungi can treat anorexia or even snap patients out of comas. The US Food and Drug Administration is now conducting clinical trials that could lead to the legalization of psilocybin-assisted psychotherapy within the next few years.